Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GE-2270A is a thiopeptide antibiotic produced by the bacterium Planobispora rosea. It acts as a potent inhibitor of bacterial protein synthesis by targeting elongation factor Tu (EF-Tu), an essential component in the translation process. Unlike other EF-Tu inhibitors, it has a distinct spectrum of activity, being particularly effective against Gram-positive bacteria and anaerobes. Structurally, it shares similarities with thiazolyl peptides such as micrococcin but functions analogously to kirromycin-like antibiotics and pulvomycin. While not approved for clinical use itself, it serves as a precursor for compounds under clinical investigation for infections like Clostridium difficile and acne[3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GE-2270A.